(92.6%) were satisfied with very good feedback (4-5 score). Also, most of them (90.8%) recommended a PPI to a friend. We didn't find any correlation between comorbidities and objective change in dimensions.
INTRODUCTION AND OBJECTIVES: Recent reports have suggested that pre-operative diabetic control may be predictive of infection rates following penile prosthesis (PP) implantation. In this study, we sought to investigate whether immediate pre-operative serum blood glucose (PBG) levels were associated with PP infection rates in diabetic patients.
METHODS: We conducted a retrospective review of 716 diabetic patients undergoing primary PP (inflatable and malleable) implantation from April 2003 to May 2018 across 15 institutions. PBG levels (within 6 hours of surgery) and Hemoglobin A1c (HbA1c) levels were recorded for each patient, along with clinical and demographic variables. Measured outcomes were rates of post-operative infection, revision and explantation. The impact of pre-operative glucose and HbA1c levels on post-operative infection rates was assessed using ANOVA and univariate analyses. The effects of age, diabetes type, diabetes related complications, body mass index, Charlson Comorbidity Index (CCI), history of immunosuppression, previous radical prostatectomy, and PP type were adjusted for, using logistic regression models.
RESULTS: Median age was 61 years (range 34-86). Median follow-up was 7 months (range 0-157). Median and mean pre-operative glucose levels were 134.0 mg/dL (range 54-344) and 143.3 mg/dL AE 45.9, respectively, and median and mean pre-operative HbA1c levels were 7.2 % (range 4.8-15.2) and 7.5% AE 1.5, respectively. Most PP were inflatable (98.6%). Devices used were AMS 700 (43.2%), AMS Ambicor (0.1%), Coloplast Titan (55.3%), and Coloplast Genesis (1.3%). Surgical approach used was penoscrotal in 74.4%, subcoronal in 23.8%, and infrapubic in 1.8%. Post-operative infection, revision, and explantation rates were 3.8%, 5.9%, and 4.5%, respectively. There was no association between PBG levels and post- METHODS: Prospective study that analyzes changes in sexual function and urinary symptoms in a group of 283 patients that underwent ES-ThuLEP. To assess the changes on erection and ejaculation, urinary symptoms and their interference on quality of life, two validated questionnaires were used: ICIQ-MLUTSsex and MSHQ-EjD. Patients were evaluated before surgery and 3 and 6 months after ES-ThuLEP. Patients with previous prostatic surgery and evidence of ED were excluded. Statistical analysis was performed by the Student t and chisquare Test and logistic regression analysis. For all statistical comparisons significance was considered at p<0.05. RESULTS: Mean age was 64.21 years. Erectile function was conserved in 95.05% and 100% of the pts at three and six months respectively. Ejaculatory function was spared in 203 pts (71.73%) at three months and in 219 pts (77.38%) at six. No significant differences were observed about erectile function before and after surgery. The ES-THULEP surgical technique do not lead to any obstructive LUTS in the follow up period.
CONCLUSIONS: ES-ThuLEP can spare ejaculatory function in a selected cohort of patients with no effects on disobstruction. Although endoscopic management of BPH (TURP and new technologies) causes retrograde ejaculation, ES-ThuLEP can offer a postoperative conserved ejaculation in the majority of cases.
